Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Heat Biologics, a US-based clinical stage pharmaceutical company, is planning to raise $4.1m in a share offering.
Subscribe to our email newsletter
The company has raised $2.8m in the current share offering, with $1.3m in shares remaining to be sold, bizjournals.com reported.
Heat Biologics is developing HIV vaccine besides other treatments for HIV infections and cancers of the ovaries, bladder, lungs and pancreas.
Heat Biologics claims that its lung-cancer treatments have progressed to Phase II clinical trials.
Heat Biologics is focused on developing its novel ‘ImPACT’ (Immune Pan-Antigen Cytotoxic Therapy) off-the-shelf therapeutic vaccines to combat a wide range of cancers and other diseases.